Overcoming resistance: Targeting the PI3K/mTOR pathway in endocrine refractory breast cancer

Cancer Biology and Therapy

Volumn 11, Issue 11, 2011, Pages 947-949

  Butt, Alison J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anti estrogens; Breast cancer; PI3 kinase; Signal transduction inhibitors; Tamoxifen

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; AROMATASE INHIBITOR; GSK 212; GSK 2126458; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL PRACTICE; DRUG EFFICACY; ESTROGEN SYNTHESIS; HUMAN; LYMPHOMA; NONHUMAN; NOTE; PROTEIN DEPHOSPHORYLATION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHATIDYLINOSITOL 3-KINASES; TAMOXIFEN; TOR SERINE-THREONINE KINASES;

EID: 79957817959     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.11.15953     Document Type: Note

References (22)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
2. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 2009; 69:1243-54.
3. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007; 8:229-39. (Pubitemid 47524868)
4. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008; 113:2385-97.
5. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28:3784-96.
6. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer 2009; 9:631-43.
7. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr-Relat Cancer 2005; 12:S47-S59. (Pubitemid 41395413)
8. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr-Relat Cancer 2004; 11:623-41. (Pubitemid 40065542)
9. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114:263-75.
10. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79:1220-6. (Pubitemid 29087902)
11. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to antihormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95:247-54. (Pubitemid 32592092)
12. Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM. The phosphatidyl inositol 3-kinase/ AKT signaling pathway in breast cancer. Cancer Metastasis Rev 2010; 29:751-9.
13. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 2001; 276:9817-24.
14. Ghayad SE, Vendrell JA, Larbi SB, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010; 126:545-62.
15. Bedard PL, Freedman OC, Howell A, Clemons M. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res Treat 2008; 108:307-17.
16. Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/ mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 2010; 5:29-57.
17. Leung E, Kim J-E, Rewcastle GW, Finlay GJ, Baguley BC. Comparison of the effects of the PI3K/ mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 2011; 11:1-9.
18. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851-63.
19. Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 2010; 1:39-43.
20. Leung E, Kannan N, Krissansen GW, Findlay MP, Baguley BC. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 2010; 9:717-24.
21. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009; 16:21-32.
22. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al. Specific apoptosis induction by the dual PI3K/mTOR inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009; 106:22299-304.